Heparin induced thrombocytopenia: diagnosis and management update

被引:195
作者
Ahmed, I.
Majeed, A.
Powell, R.
机构
[1] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England
[2] Worcester Royal Hosp, Worcester, England
[3] Leicester Gen Hosp, Leicester LE5 4PW, Leics, England
关键词
D O I
10.1136/pgmj.2007.059188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; rather, HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. A number of laboratory tests are available to confirm the diagnosis; however, when HIT is clinically suspected, treatment should not be withheld pending the result. Fortunately, therapeutic strategies have been refined, and new and effective therapeutic agents are available. Treatment options are focused on inhibiting thrombin formation or direct thrombin inhibition. Warfarin should not be used until the platelet count has recovered.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 53 条
[1]  
Alsoufi Bahaaldin, 2004, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V7, P155, DOI 10.1053/j.pcsu.2004.02.024
[2]  
AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21
[3]   Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia [J].
Andreescu, ACM ;
Possidente, C ;
Hsieh, M ;
Cushman, M .
PHARMACOTHERAPY, 2000, 20 (08) :974-980
[4]   Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study [J].
Bittl, JA ;
Chaitman, BR ;
Feit, F ;
Kimball, W ;
Topol, EJ .
AMERICAN HEART JOURNAL, 2001, 142 (06) :952-959
[5]   HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS - CLINICAL AND LABORATORY STUDIES [J].
BOSHKOV, LK ;
WARKENTIN, TE ;
HAYWARD, CPM ;
ANDREW, M ;
KELTON, JG .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (02) :322-328
[6]  
Bradner J, 2004, BLOOD, V104, p492A
[7]  
Campbell K R, 2000, J Invasive Cardiol, V12 Suppl F, p14F
[8]   Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia [J].
Carlsson, LE ;
Lubenow, N ;
Blumentritt, C ;
Kempf, R ;
Papenberg, S ;
Schröder, W ;
Eichler, P ;
Herrmann, FH ;
Santoso, S ;
Greinacher, A .
PHARMACOGENETICS, 2003, 13 (05) :253-258
[9]   Heparin-induced thrombocytopenia [J].
Chong, BH .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1471-1478
[10]   Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis - A clinical outcome study [J].
Chong, BH ;
Gallus, AS ;
Cade, JF ;
Magnani, H ;
Manoharan, A ;
Oldmeadow, M ;
Arthur, C ;
Rickard, K ;
Gallo, J ;
Lloyd, J ;
Seshadri, P ;
Chesterman, CN .
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (05) :1170-1175